BioSpace

Agios axes 100-plus R&D roles while awaiting FDA decision

After the FDA delayed a decision for Agios Pharmaceuticals’ sickle cell disease candidate, the biopharma is letting go of more than 35% of its R&D employees.

By BioSpace

1 min read
Agios axes 100-plus R&D roles while awaiting FDA decision
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights